AbbVie and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is excited to announce that its novel oral ketamine analog, Ketamir-2, has shown greater pain ...
This technology approach marks a significant step forward in mental health care, with the potential to make impactful changes in how these conditions are managed.
The other five goals constitute a category of “knowledge, skills, and values consistent with a liberal arts education that are further developed in psychology”: This immersive Picture Story features ...